Frontiers in Pharmacology (Sep 2022)

A bibliometric research based on hotspots and frontier trends of denosumab

  • Bolin Ren,
  • Bolin Ren,
  • Xiaolei Ren,
  • Xiaolei Ren,
  • Lu Wang,
  • Chao Tu,
  • Chao Tu,
  • Wenchao Zhang,
  • Wenchao Zhang,
  • Zhongyue Liu,
  • Zhongyue Liu,
  • Lin Qi,
  • Lin Qi,
  • Lu Wan,
  • Lu Wan,
  • Ke Pang,
  • Ke Pang,
  • Cheng Tao,
  • Zhihong Li,
  • Zhihong Li

DOI
https://doi.org/10.3389/fphar.2022.929223
Journal volume & issue
Vol. 13

Abstract

Read online

Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic Co-Occurrence Analysis System (BICOMB) and graph clustering toolkit (gCLUTO). The results show that the number of denosumab-related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc. being the most influential in the past 10 years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, Yukio Nakamura, Takako Suzuki, and Hiroyuki Kato, joined the field relatively late but produced the most. The clinical comparison and combination of denosumab with other drugs in the treatment of osteoporosis was the most significant focus of research. Drug withdrawal rebound and management strategies have gained more attention and controversy recently. MeSH analysis revealed eight major categories of research hotspots. Among them, exploring the multiple roles of the RANK-RANKL-OPG system in tumor progression, metastasis, and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for internal spinal fixation and orthopedic prosthesis implantation. Taken together, the advantages of denosumab were broad and cost-effective. However, there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, a high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures, which need to be adequately solved.

Keywords